[Oral administration of "Infectvac" for prevention of acute respiratory tract infections].
The efficacy of a newly developed polyvalent bacterial lysat vaccine "Infectvac" was tested in experimental studies in animals. It was shown that a local application (oral, aerogenic) prevent the animals from a lethal bacterial (S. pneumoniae) or viral (A/PR/8/34) infection. In first clinical trials a good compatibility of the drug was demonstrated.